Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses

References

• Wenger DA, Luzi P, Rafi MA. Lysosomal storage diseases: heterogeneous group of disorders. BioImpacts. 2013;34:145.
   PubMedGoogle Scholar
• Hollak CE, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis. 2014;37:587–598.
   PubMed Web of Science ®Google Scholar
• Mohamed FE, Al-Gazali L, Al-Jasmi F, et al. Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises. Front Pharmacol. 2017;8:448.
   PubMed Web of Science ®Google Scholar
• Platt FM, d’Azzo A, Davidson BL, et al. Lysosomal storage diseasesNat Rev Dis Primers. 2018;4:1–25.
   Google Scholar
• Gaffke L, Pierzynowska K, Podlacha M, et al. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int. 2019. DOI:https://doi.org/10.1002/cbin.11275.
   Google Scholar
• Gaffke L, Pierzynowska K, Podlacha M, et al. Underestimated aspect of mucopolysaccharidosis pathogenesis: global changes in cellular processes revealed by transcriptomic studies. Int J Mol Sci. 2020;21. DOI:https://doi.org/10.3390/ijms21041204.
   Google Scholar
• Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology. 2011;50:v49–v59.
   PubMed Web of Science ®Google Scholar
• Schuh RS, Baldo G, Teixeira HF. Nanotechnology applied to treatment of mucopolysaccharidoses. Expert Opin Drug Deliv. 2016;13(12):1709–1718.
   Google Scholar
• Noh H, Lee J. Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther. 2014;39:215–224.
   PubMed Web of Science ®Google Scholar
• Peck SH, Casal ML, Malhotra NR, et al. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses. Mol Genet Metab. 2016;118:232–243.
   PubMed Web of Science ®Google Scholar
• Sawamoto K, Stapleton M, Alméciga-Díaz CJ, et al. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;1–32. DOI:https://doi.org/10.1007/s40265-019-01147-4.
   Google Scholar
• Macauley SL. Combination therapies for lysosomal storage diseases: a complex answer to a simple problemPediatr Endocrinol Rev. 2016;13:639.
   PubMed Web of Science ®Google Scholar
• Rafi MA. Gene therapy for CNS diseases–Krabbe disease. Bioimpacts. 2016;6:69.
   PubMed Web of Science ®Google Scholar
• Fathi M, Barar J. Perspective highlights on biodegradable polymeric nanosystems for targeted therapy of solid tumors. Bioimpacts. 2017;7:49.
   PubMed Web of Science ®Google Scholar
• Schuh RS, É P, Pasqualim G, et al. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system. J Control Release. 2018;288:23–33.
   PubMed Web of Science ®Google Scholar
• Schuh RS, Gonzalez EA, Tavares AMV, et al. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice. Gene Ther. 2020;27:74–84.
   PubMed Web of Science ®Google Scholar
• Ou L, Przybilla MJ, Ahlat O, et al. A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I. Mol Ther. 2020. DOI:https://doi.org/10.1016/j.ymthe.2020.03.018.
   Google Scholar
• Poletto E, Baldo G, Gomez-Ospina N. Genome editing for mucopolysaccharidoses. Int J Mol Sci. 2020;21:500.
   Web of Science ®Google Scholar
• Laoharawee K, DeKelver RC, Podetz-Pedersen KM, et al. Dose-dependent prevention of metabolic and neurologic disease in murine MPS II by ZFN-mediated in vivo genome editing. Mol Ther. 2018;26:1127–1136.
   PubMed Web of Science ®Google Scholar
• Ou L, DeKelver RC, Rohde M, et al. ZFN-mediated in vivo genome editing corrects murine Hurler syndrome. Mol Ther. 2019;27:178–187.
   PubMed Web of Science ®Google Scholar
• Taylor M, Khan S, Stapleton M, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transplant. 2019;25:e226–e46.
   PubMed Web of Science ®Google Scholar
• Parenti G, Pignata C, Vajro P, et al. New strategies for the treatment of lysosomal storage diseases. Int J Mol Med. 2013;31:11–20.
   PubMed Web of Science ®Google Scholar
• Chen HH, Sawamoto K, Mason RW, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet. 2019;64:1153–1171.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107:513–520.
   PubMed Web of Science ®Google Scholar
• Li M. Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases. Pediatr Ann. 2018;47:e191–e7.
   PubMed Web of Science ®Google Scholar
• Safary A, Akbarzadeh Khiavi M, Mousavi R, et al. Enzyme replacement therapies: what is the best option? Bioimpacts. 2018;8:153–157.
   PubMed Web of Science ®Google Scholar
• Mikulka CR, Sands MS. Treatment for Krabbe’s disease: finding the combination. J Neurosci Res. 2016;94:1126–1137.
   PubMed Web of Science ®Google Scholar
• Grewal SS, Wynn R, Abdenur JE, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7:143–146.
   PubMed Web of Science ®Google Scholar
• Cox-Brinkman J, Boelens J, Wraith J, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006;38:17–21.
   PubMed Web of Science ®Google Scholar
• Tolar J, Grewal S, Bjoraker K, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2008;41:531–535.
   PubMed Web of Science ®Google Scholar
• Kuehn SC, Koehne T, Cornils K, et al. Impaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I. Hum Mol Genet. 2015;24:7075–7086.
   PubMed Web of Science ®Google Scholar
• White KK, Sousa T. Mucopolysaccharide disorders in orthopaedic surgery. J Am Acad Orthop Surg. 2013;21:12–22.
   PubMed Web of Science ®Google Scholar
• Fecarotta S, Tarallo A, Damiano C, et al. Pathogenesis of mucopolysaccharidoses, an update. Int J Mol Sci. 2020;21:2515. .
   Web of Science ®Google Scholar
• Clarke LA. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology. 2011;50:v13–v8.
   PubMed Web of Science ®Google Scholar
• Nan H, Park C, Maeng S. Mucopolysaccharidoses I and II: brief review of therapeutic options and supportive/palliative therapies. BioMed Res Int. 2020;2020:240840.
   Web of Science ®Google Scholar
• Leone A, Rigante D, Amato DZ, et al. Spinal involvement in mucopolysaccharidoses: a review. Child’s Nerv Syst. 2015;31:203–212.
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Alméciga-Díaz CJ, Montaño AM, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab. 2015;114:94–109.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang W, Shi H, et al. Mucopolysaccharidosis I mutations in Chinese patients: identification of 27 novel mutations and 6 cases involving prenatal diagnosis. Clin Genet. 2012;81:443–452.
   PubMed Web of Science ®Google Scholar
• Willoughby CE, Ponzin D, Ferrari S, et al. Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function–a review. Clin Experiment Ophthalmol. 2010;38:2–11.
   PubMed Web of Science ®Google Scholar
• Summers CG, Ashworth JL. Ocular manifestations as key features for diagnosing mucopolysaccharidoses. Rheumatology. 2011;50:v34–v40.
   PubMed Web of Science ®Google Scholar
• Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015;9:1633.
   PubMed Web of Science ®Google Scholar
• Summers CG, Fahnehjelm KT, Pitz S, et al. Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy–a review. Clin Experiment Ophthalmol. 2010;38:34–42.
   Web of Science ®Google Scholar
• Koseoglu ST, Harmatz P, Turbeville S, et al. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy. Int Ophthalmol. 2009;29:267–269.
   PubMedGoogle Scholar
• Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183–1197.
   PubMed Web of Science ®Google Scholar
• Brands MM, Frohn‐Mulder IM, Hagemans ML, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme‐replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis.2013;36:227–234.
   PubMed Web of Science ®Google Scholar
• Braunlin E, Rosenfeld H, Kampmann C, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis. 2013;36:385–394.
   PubMed Web of Science ®Google Scholar
• Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50:v4–v12.
   PubMed Web of Science ®Google Scholar
• Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms. Mol Genet Metab. 2017;122s:1–7.
   PubMed Web of Science ®Google Scholar
• Holt J, Poe MD, Escolar ML. Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J Pediatr. 2011;159(320–6):e2.
   Google Scholar
• Ullman JC, Arguello A, Getz JA, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12. DOI:https://doi.org/10.1126/scitranslmed.aay1163.
   Google Scholar
• Saville JT, McDermott BK, Fuller M. Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse. Mol Genet Metab. 2018;123:112–117.
   PubMed Web of Science ®Google Scholar
• Lehman TJ, Miller N, Norquist B, et al. Diagnosis of the mucopolysaccharidoses. Rheumatology. 2011;50:v41–v8.
   PubMed Web of Science ®Google Scholar
• Filocamo M, Tomanin R, Bertola F, et al. Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know. Ital J Pediatr. 2018;44:129.
   PubMed Web of Science ®Google Scholar
• Khan SA, Mason RW, Giugliani R, et al. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Mol Genet Metab. 2018;125:44–52.
   PubMed Web of Science ®Google Scholar
• Erickson RP, Sandman R, Epstein CJ. Lack of relationship between blood and urine levels of glycosaminoglycans and lysomal enzymes. Biochem Med. 1975;12:331–339.
   PubMed Web of Science ®Google Scholar
• Kubaski F, De Oliveira Poswar F, Michelin-Tirelli K, et al. Diagnosis of Mucopolysaccharidoses. Diagnostics (Basel). 2020;10. DOI:https://doi.org/10.3390/diagnostics10030172.
   Google Scholar
• Dierenfeld AD, McEntee MF, Vogler CA, et al. Replacing the enzyme α-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med. 2010;2:60ra89–60ra89.
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab. 2013;109:33–40.
   PubMed Web of Science ®Google Scholar
• Gabrielli O, Clarke LA, Bruni S, et al. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010;125:e183–e7.
   PubMed Web of Science ®Google Scholar
• Fujitsuka H, Sawamoto K, Peracha H, et al. Biomarkers in patients with mucopolysaccharidosis type II and IV. Mol Genet Metab Rep. 2019;19:100455.
   PubMed Web of Science ®Google Scholar
• Bobillo Lobato J, Jiménez Hidalgo M, Jiménez Jiménez LM. Biomarkers in Lysosomal Storage Diseases. Diseases. 2016;4. DOI:https://doi.org/10.3390/diseases4040040.
   Google Scholar
• Safary A, Moniri R, Hamzeh-Mivehroud M, et al. Molecular characterization of genes coding pharmaceutically important enzymes from halo-thermo tolerant bacillus. Adv Pharm Bull. 2016;6:551.
   PubMed Web of Science ®Google Scholar
• Safary A, Khiavi MA, Omidi Y, et al. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis. Cell Mol Life Sci. 2019;1–19. DOI:https://doi.org/10.1007/s00018-019-03135-z.
   Google Scholar
• Desnick R, Schuchman E. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet. 2012;13:307–335.
   PubMed Web of Science ®Google Scholar
• Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36:1110–1122.
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Treatment perspectives for the lysosomal storage diseases. Expert Opin Emerg Drugs. 2008;13:197–211.
   PubMed Web of Science ®Google Scholar
• Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017. https://doi.org/10.1016/j.addr.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Lib. 2016. https://doi.org/10.1002/14651858.CD009354.pub4.
   Google Scholar
• Jung G, Pabst M, Neumann L, et al. Characterization of alpha-l-Iduronidase (Aldurazyme(R)) and its complexes. J Proteomics. 2013;80:26–33.
   PubMed Web of Science ®Google Scholar
• Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007;91:61–68.
   PubMed Web of Science ®Google Scholar
• Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004;83:163–174.
   PubMed Web of Science ®Google Scholar
• Dickson PI, Hanson S, McEntee MF, et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab. 2010;101:115–122.
   PubMed Web of Science ®Google Scholar
• Dickson PI, Kaitila I, Harmatz P, et al. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Mol Genet Metab. 2015;116:69–74.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Giugliani L, De Oliveira Poswar F, et al. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. Orphanet J Rare Dis. 2018;13:110.
   PubMed Web of Science ®Google Scholar
• Preusser-Kunze A, Mariappan M, Schmidt B, et al. Molecular characterization of the human Calpha-formylglycine-generating enzyme. J Biol Chem. 2005;280:14900–14910.
   PubMed Web of Science ®Google Scholar
• Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31:309–315.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase® Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99:18–25.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90:329–337.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Eto Y, Sakai N, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1/2 trial. Mol Ther. 2019;27:456–464.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Yu Z-F, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33:51–60.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148(533–9):e6.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz IVD, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469–475.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681–e9.
   PubMed Web of Science ®Google Scholar
• Rivera-Colon Y, Schutsky EK, Kita AZ, et al. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J Mol Biol. 2012;423:736–751.
   PubMed Web of Science ®Google Scholar
• Olarte-Avellaneda S, Rodriguez-Lopez A, Almeciga-Diaz CJ, et al. Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: an update in genotype-phenotype correlation for Morquio A. Mol Biol Rep. 2014;41:7073–7088.
   PubMed Web of Science ®Google Scholar
• Dung VC, Tomatsu S, Montano AM, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab. 2013;110:129–138.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tomatsu S, Mason RW, et al. Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis II, IVA, and IVB. JIMD Rep. 2015;21:1–13.
   PubMedGoogle Scholar
• Ellsworth KA, Pollard LM, Cathey S, et al. Measurement of elevated concentrations of urine keratan sulfate by UPLC-MSMS in lysosomal storage disorders (LSDs): comparison of urine keratan sulfate levels in MPS IVA versus other LSDs. JIMD Rep. 2017;34:11–18.
   PubMedGoogle Scholar
• Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111:63–72.
   PubMed Web of Science ®Google Scholar
• Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37:979–990.
   PubMed Web of Science ®Google Scholar
• Qi Y, McKeever K, Taylor J, et al. Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials. Clin Pharmacokinet. 2018;1–11. https://doi.org/10.1007/s40262-018-0726-6.
   Google Scholar
• McCafferty EH, Scott LJ. Vestronidase Alfa: a Review in Mucopolysaccharidosis VII. BioDrugs. 2019;33:233–240.
   PubMed Web of Science ®Google Scholar
• Harmatz P, Whitley CB, Wang RY, et al. A novel, randomized, placebo-controlled, blind-start, single-crossover phase 3 study to assess the efficacy and safety of UX003 (rhGUS) enzyme replacement therapy in patients with MPS VII. Mol Genet Metab. 2017;120:S63.
   Web of Science ®Google Scholar
• Yogalingam G, Luu AR, Prill H, et al. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis. PLoS One. 2019;14:e0207836.
   PubMed Web of Science ®Google Scholar
• Malm G, Månsson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30‐year period. Acta Paediatr. 2010;99:1253–1257.
   PubMed Web of Science ®Google Scholar
• Birrane G, Dassier A-L, Romashko A, et al. Structural characterization of the α-N-acetylglucosaminidase, a key enzyme in the pathogenesis of Sanfilippo syndrome B. J Struct Biol. 2019;205:65–71.
   PubMed Web of Science ®Google Scholar
• Prill H, Luu A, Yip B, et al. Differential uptake of NAGLU-IGF2 and unmodified NAGLU in cellular models of Sanfilippo syndrome Type B.Mol Ther Methods Clin Dev. 2019;14:56-63.
   PubMed Web of Science ®Google Scholar
• Aoyagi-Scharber M, Crippen-Harmon D, Lawrence R, et al. Clearance of heparan sulfate and attenuation of CNS pathology by intracerebroventricular BMN 250 in Sanfilippo type B mice. Mol Ther Methods Clin Dev. 2017;6:43–53.
   Google Scholar
• Muschol N, Cleary M, Couce ML, et al. ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB). Mol Genet Metab. 2018;123(2):S102.
   Google Scholar
• Rossomando A, Chen LL, Ciatto C, et al. SBC-103, A recombinant human alpha-N-acetylglucosaminidase, demonstrates mannose-6-phosphate receptor dependent transport in an in vitro blood-brain barrier model. Mol Genet Metab. 2014;2:S91.
   Web of Science ®Google Scholar
• Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA. 2005;102:14777–14782.
   PubMed Web of Science ®Google Scholar
• Salvalaio M, Rigon L, Belletti D, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS One. 2016;11:e0156452.
   PubMed Web of Science ®Google Scholar
• Jafari B, Pourseif MM, Barar J, et al. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin Drug Deliv. 2019;16:583–605.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Blood-Brain Barrier BJ. Effectiveness of Therapy Against Brain Tumors. In: Farassati F, editor. Novel Therapeutic Concepts in Targeting Glioma. London: IntechOpen Limited; 2012. p. 111–40.
   Google Scholar
• Mucopolysacccharidoses GR. From understanding to treatment, a century of discoveries. Genet Mol Biol. 2012;35:924–931.
   PubMed Web of Science ®Google Scholar
• Urayama A, Grubb JH, Sly WS, et al. Mannose 6-phosphate receptor–mediated transport of sulfamidase across the blood–brain barrier in the newborn mouse. Mol Ther. 2008;16:1261–1266.
   PubMed Web of Science ®Google Scholar
• Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23:1138–1148.
   PubMed Web of Science ®Google Scholar
• Pan D. Cell-and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses. Curr Pharm Biotechnol. 2011;12:884–896.
   PubMed Web of Science ®Google Scholar
• Sato Y, Okuyama T. Novel enzyme replacement therapies for neuropathic mucopolysaccharidoses. Int J Mol Sci. 2020;21:400.
   Web of Science ®Google Scholar
• Pierzynowska K, Kamińska T, Węgrzyn G. One drug to treat many diseases: unlocking the economic trap of rare diseases. Metab Brain Dis. 2020;35:1237–1240.
   PubMed Web of Science ®Google Scholar
• Kobayashi H. Recent trends in mucopolysaccharidosis research. J Hum Genet. 2019;64:127–137.
   PubMed Web of Science ®Google Scholar
• Kirkegaard T. Emerging therapies and therapeutic concepts for lysosomal storage diseases. Expert Opin Orphan Drugs. 2013;1:385–404.
   Web of Science ®Google Scholar
• Montaño AM, Lock-Hock N, Steiner RD, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016. jmedgenet-2015-103322. https://doi.org/10.1136/jmedgenet-2015-103322.
   Google Scholar
• Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5:295–307.
   PubMed Web of Science ®Google Scholar
• Yabe H, Tanaka A, Chinen Y, et al. Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab. 2016;117:84–94.
   PubMed Web of Science ®Google Scholar
• Turbeville S, Nicely H, Rizzo JD, et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab. 2011;102:111–115.
   PubMed Web of Science ®Google Scholar
• Wang J, Luan Z, Jiang H, et al. Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis—a ten-year report from the China children transplant group. Biol Blood Marrow Transplant. 2016;22:2104–2108.
   PubMed Web of Science ®Google Scholar
• Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol. 2010;47:59–69.
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Panoskaltsis-Mortari A, Haddad IY, et al. Inflammatory cytokines and the development of pulmonary complications after allogeneic hematopoietic cell transplantation in patients with inherited metabolic storage disorders. Biol Blood Marrow Transplant. 2006;12:430–437.
   PubMed Web of Science ®Google Scholar
• Gassas A, Sung L, Doyle J, et al. Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature Bone marrow transplantation. Bone Marrow Transplant. 2003;32:213–215.
   Google Scholar
• Soni S, Hente M, Breslin N, et al. Pre‐stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post‐transplant: a case report. Pediatr Transplant. 2007;11:563–567.
   PubMed Web of Science ®Google Scholar
• Bijarnia S, Shaw P, Vimpani A, et al. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome. J Paediatr Child Health. 2009;45:469–472.
   PubMed Web of Science ®Google Scholar
• Wynn RF, Mercer J, Page J, et al. Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr. 2009;154:135–139.
   PubMed Web of Science ®Google Scholar
• De Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123:19–29.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Miller W, Orchard PJ, et al. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10year combined experience of 2 centres. Mol Genet Metab. 2016;117:373–377.
   PubMed Web of Science ®Google Scholar
• Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2013;162(375–80):e1.
   Google Scholar
• Santi L, De Ponti G, Dina G, et al. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model. Mol Genet Metab. 2020;130:197–208.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Liao A, O’Leary C, et al. Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I. Mol Ther Methods Clin Dev. 2019;13:321–333.
   PubMed Web of Science ®Google Scholar
• Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome. Mol Gene Metabol Rep. 2014;1:184–196.
   PubMedGoogle Scholar
• Akiyama K, Shimada Y, Higuchi T, et al. Enzyme augmentation therapy enhances the therapeutic efficacy of bone marrow transplantation in mucopolysaccharidosis type II mice. Mol Genet Metab. 2014;111:139–146.
   PubMed Web of Science ®Google Scholar
• Sillence D, Waters K, Donaldson S, et al. Combined enzyme replacement therapy and hematopoietic stem cell transplantation in mucopolysacharidosis type VI. 2011;2011/2(Springer):103–6. JIMD Reports-Case and Research Reports.
   Google Scholar
• Sands MS, Vogler C, Torrey A, et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest. 1997;99:1596–1605.
   PubMed Web of Science ®Google Scholar
• Simonaro CM, Gea Y, Eliyahua E, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses. PNAS. 2010;107:222–227.
   PubMed Web of Science ®Google Scholar
• Ausseil J, Desmaris N, Bigou S, et al. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One. 2008;3:e2296.
   PubMed Web of Science ®Google Scholar
• Simonaro CM, D’Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2008;172:112–122.
   PubMed Web of Science ®Google Scholar
• Schuchman EH, Ge Y, Lai A, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One. 2013;8:e54459.
   PubMed Web of Science ®Google Scholar
• Hennermann JB, Gökce S, Solyom A, et al. Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis. 2016;39:831–837.
   PubMed Web of Science ®Google Scholar
• Eliyahu E, Wolfson T, Ge Y, et al. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One. 2011;6:e22447. .
   PubMed Web of Science ®Google Scholar
• Aronovich EL, Hackett PB. Lysosomal storage disease: gene therapy on both sides of the blood–brain barrier. Mol Genet Metab. 2015;114:83–93.
   PubMed Web of Science ®Google Scholar
• Schuh RS, De Carvalho TG, Giugliani R, et al. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers. Eur J Pharm Biopharm. 2018;122:158–166.
   PubMed Web of Science ®Google Scholar
• Belur LR, Temme A, Podetz-Pedersen KM, et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther. 2017;28:576–587.
   PubMed Web of Science ®Google Scholar
• Janson CG, Romanova LG, Leone P, et al. Comparison of endovascular and intraventricular gene therapy with adeno-associated virus–α-l-iduronidase for hurler disease. Neurosurgery. 2013;74:99–111.
   Web of Science ®Google Scholar
• McIntyre C, Derrick‐Roberts AL, Byers S, et al. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral‐mediated gene delivery. J Gene Med. 2014;16:374–387.
   PubMed Web of Science ®Google Scholar
• Gurda BL, Adg DL, Bell P, et al. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther. 2016;24:206–216.
   PubMed Web of Science ®Google Scholar
• Wolf DA, Banerjee S, Hackett PB, et al. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert Opin Drug Deliv. 2015;12:283–296.
   PubMed Web of Science ®Google Scholar
• Sawamoto K, Chen -H-H, Alméciga-Díaz CJ, et al. Gene therapy for Mucopolysaccharidoses. Mol Genet Metab. 2018;123:59–68.
   PubMed Web of Science ®Google Scholar
• Alliegro M, Ferla R, Nusco E, et al. Therapy reduces the frequency of enzyme replacement therapy in a mouse model of lysosomal storage disease. Mol Ther. 2016;24:2054–2063.
   PubMed Web of Science ®Google Scholar
• Lamanna WC, Lawrence R, Sarrazin S, et al. A genetic model of substrate reduction therapy for mucopolysaccharidosis. J Biol Chem. 2012;287:36283–36290.
   PubMed Web of Science ®Google Scholar
• Ceravolo F, Grisolia M, Sestito S, et al. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report. J Med Case Rep. 2017;11:19.
   PubMedGoogle Scholar
• Macauley SL, Roberts MS, Wong AM, et al. Synergistic effects of central nervous system‐directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann Neurol. 2012;71:797–804.
   PubMed Web of Science ®Google Scholar
• Rafi MA, Rao HZ, Luzi P, et al. Long-term improvements in lifespan and pathology in CNS and PNS after BMT plus one intravenous injection of AAVrh10-GALC in twitcher mice. Mol Ther. 2015;23:1681–1690.
   PubMed Web of Science ®Google Scholar
• Boyd RE, Lee G, Rybczynski P, et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem. 2013;56:2705–2725.
   PubMed Web of Science ®Google Scholar
• Chang HH, Asano N, Ishii S, et al. Hydrophilic iminosugar active‐site‐specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients. Febs J. 2006;273:4082–4092.
   PubMed Web of Science ®Google Scholar
• Porto C, Cardone M, Fontana F, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther. 2009;17:964–971.
   PubMed Web of Science ®Google Scholar
• Porto C, Pisani A, Rosa M, et al. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis. 2012;35:513–520.
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17:1065.
   Web of Science ®Google Scholar
• Hawkins-Salsbury JA, Shea L, Jiang X, et al. Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. J Neurosci. 2015;35:6495–6505.
   PubMed Web of Science ®Google Scholar
• Galbiati F, Givogri M, Cantuti L, et al. Combined hematopoietic and lentiviral gene‐transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease. J Neurosci Res. 2009;87:1748–1759.
   PubMed Web of Science ®Google Scholar
• Rafi MA. Gene and stem cell therapy: alone or in combination? Bioimpacts. 2011;1:213.
   PubMedGoogle Scholar
• Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther. 2010;18:873–880.
   PubMed Web of Science ®Google Scholar
• Strazza M, Luddi A, Carbone M, et al. Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Mol Genet Metab. 2009;97:27–34.
   PubMed Web of Science ®Google Scholar
• Lotfi P, Tse DY, Di Ronza A, et al. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency. Autophagy. 2018;14:1419–1434.
   PubMed Web of Science ®Google Scholar
• Pierzynowska K, Gaffke L, Podlacha M, et al. Autophagy: controversies on the Contribution of the Process to the Pathogenesis and Possible Therapeutic Applications. Neuromolecular Med. 2020;22:25–30.
   PubMed Web of Science ®Google Scholar